Introduction {#s1}
============

Atrial fibrillation (AF) is the most common arrhythmia in the world affecting 1-2% of the general population \[[@R01]\]. AF incidence is expected to more than double, from 1.2 million cases in 2010 to 2.6 million cases in 2030, consequently AF prevalence is projected to increase from 5.2 million in 2010 to 12.1 million cases in 2030 \[[@R02]\]. It is known that AF increases the risk of stroke; therefore, the first priority is stroke prophylaxis via oral anticoagulation if the patient is a suitable candidate \[[@R03]\]. Then, consideration should be made whether intervention via rate or rhythm control therapy should be attempted or whether referral to an electrophysiology (EP) clinic is necessary. It has been shown that managing AF patients in specialty clinics reduces the incidence of AF-related hospitalizations and stroke \[[@R04]\].

Of particular concern is the newly diagnosed asymptomatic AF patient. About 33% of patients are unaware of having AF and thus may have delayed diagnosis and treatment \[[@R05]\]. This is of particular importance because increased rates of stroke and death have been associated with patients in AF \[[@R06]\]. Moreover, patients who deny symptoms may have grown tolerant of their condition, or do not realize the extent of their symptoms. Hence, it can be challenging to advise a new, asymptomatic patient to pursue treatment of their AF.

We hypothesized that asymptomatic to minimally symptomatic patients would realize the true extent of their symptoms and the amount of symptom compensation once they converted to sinus rhythm. We quantified this using the Canadian Cardiovascular Society Severity of AF (CCS-SAF) score and follow-up phone calls with these patients.

Methods {#s2}
=======

The SMART study is a single-center prospective cohort study of patients with AF, measuring AF symptoms and health outcomes. Details of the SMART study have been previously described \[[@R07]\]. In brief, participants were enrolled through Outpatient Electrophysiology Clinics at the University of North Carolina Chapel Hill when referred for management of AF. Participants were excluded if they were planning to move from the local area within 3 years of enrollment or were less than 18 years of age. The appropriate institutional review board approved the study and all participants provided written informed consent.

Upon enrollment, participants completed a baseline questionnaire of general demographic information and measures of physical and psychological health and were assigned a baseline CCS-SAF score by the attending physician. Patients receiving a CCS-SAF score of 0 - 1 also completed a follow-up phone call questionnaire at least 6 months after initiation of intervention, asking: 1) Since your treatment for atrial fibrillation, have your symptoms improved? If so, can you estimate the percentage improvement on a scale from 0% to 100%? 2) On a scale of 0 - 4, 0 representing no symptoms and 4 the worst possible symptoms, how would you rate your symptom level today (patient-assigned SAF score)? 3) At your initial visit to the EP clinic (pre-treatment) your provider assigned you a score of \_, on a scale of 0 - 4. In hindsight, knowing your symptom level today, was that number accurate? If no, would you want to revise it?

Baseline demographics and follow-up data were securely archived using REDCap, an online database used for data collection. Paired *t*-test was used for statistical analysis.

Results {#s3}
=======

Of the 800 patients enrolled in the SMART study to date, 82 patients have qualified as asymptomatic or minimally symptomatic; 48 patients have returned for follow-up in our EP clinic and have complete data available. The 48 patients with complete data available formed our final study group. Baseline demographics for the patients included in the discussion, as well as patients excluded from the study, are provided in [Table 1](#T1){ref-type="table"} and were statistically no different. Of the included 48 patients, 18 patients (37.5%) received rate control therapy and the remaining 30 patients (62.5%) received rhythm control therapy by way of antiarrhythmic medications, or a combination of antiarrhythmic medications plus catheter ablation. The patients were placed on rate control or rhythm control therapy based on what their provider believed to best confer to the patients' needs, independent of our study.

###### Baseline Demographics for Patients Included in Discussion and Patients Excluded From Discussion

                       Patients included (n = 48)   Patients excluded (n = 34)   
  -------------------- ---------------------------- ---------------------------- ----
  Age (years)          71.1 ± 8.80                  68.2 ± 16.2                  NS
  White                93.75% (45)                  85% (29)                     NS
  Male                 65% (31)                     68% (23)                     NS
  BMI                  30.48 ± 6.28                 32.13 ± 9.19                 NS
  HTN                  41.67% (20)                  44% (15)                     NS
  CHF                  6.25% (3)                    12% (4)                      NS
  Beta blocker         60.4% (29)                   68% (23)                     NS
  CCB                  18.8% (9)                    24% (8)                      NS
  ACE/ARB              29.2% (14)                   41% (14)                     NS
  Statin               35.4% (17)                   47% (16)                     NS
  Persistent AF        29.2% (14)                   35% (12)                     NS
  Baseline AF burden   44.8±46.95%\*                54.73±48.91%\*\*             NS
  CHADS2 score         1.77 ± 1.36                  1.41 ± 1.10                  NS
  CHADS-VASc score     2.85 ± 1.70                  2.44 ± 1.58                  NS

Comparison between the two groups yielded non-significant (NS) difference in each parameter. \*Baseline AF burden available in only 42 patients included in discussion; \*\*Baseline AF burden available in only 28 patients excluded from discussion.

Patients were contacted by phone 499 ± 250 days after initiation of treatment and asked to assign a retrospective pre-intervention CCS-SAF score and a post-intervention CCS-SAF score. These scores were 1.69 ± 1.36 and 0.52 ± 0.80 respectively (P \< 0.0001, not shown in figure). Symptoms improved in 37 of the 48 (77.1%) patients surveyed; when asked to quantify their improvement from 0% improved to 100% improved, those who improved were on average 72.4% improved from baseline.

Furthermore, we examined CCS-SAF score improvement in patients who received rate control (18 patients), versus those who received rhythm control (30 patients). In both populations significant CCS-SAF score improvement was observed (P = 0.005 and P \< 0.0001 respectively) ([Fig. 1a](#F1){ref-type="fig"}). Also, we examined CCS-SAF improvement in patients suffering from paroxysmal AF and persistent AF at baseline. Again, in both populations significant CCS-SAF score improvement was observed (P = 0.0002 and P = 0.007 respectively) ([Fig. 1b](#F1){ref-type="fig"}).

![Summarization of treatment effect on CCS-SAF score in subpopulations in our low SAF cohort. (a) Our subpopulations of rhythm control (n = 30) and rate control (n=18). (b) Our subpopulations of persistent AF (n = 14) and paroxysmal AF (n = 34).](jocmr-07-690-g001){#F1}

Discussion {#s4}
==========

In our cohort, minimally symptomatic patients benefitted from rhythm control therapy once converted to sinus rhythm (P \< 0.0001; [Fig. 1a](#F1){ref-type="fig"}). Unexpectedly, we also found patients on rate control therapy derived significant symptom improvement as well (P = 0.005; [Fig. 1a](#F1){ref-type="fig"}). Since we first presented our data, asymptomatic longstanding persistent AF patients have been found to experience symptom relief following catheter ablation \[[@R08], [@R09]\]. Our results demonstrate that in addition to persistent AF patients, paroxysmal AF patients also derive significant symptom reduction from intervention (P = 0.0002; [Fig. 1b](#F1){ref-type="fig"}). Our results suggest asymptomatic to minimally symptomatic AF patients compensate for their symptoms at baseline and achieve symptom mitigation following intervention.

Patients living with untreated AF are at risk for embolic events. Paroxysmal AF, if transient, infrequent, and sometimes asymptomatic, may be undetected on continuous telemetry and 24 or 48-h Holter monitors. A prospective study of 2,580 subjects, age ≥ 65 years, with hypertension and no history of AF who had recent implantation of a pacemaker or defibrillator (ASSERT) links subclinical AF and cryptogenic stroke \[[@R10]\]. In another study among subjects with at least 3 months of continuous monitoring who experienced ischemic stroke or systemic embolism (n = 51), subclinical AF was detected in 26 (51%) subjects \[[@R11]\]. These results suggest that there is no temporal relationship between asymptomatic or undetected AF and stroke; however, it is shown that subclinical AF is associated with an increased risk of embolic events.

Recent studies support enhanced surveillance in patients who experience cryptogenic stroke or TIA for several weeks to rule out subclinical AF. In the CRYSTAL AF trial, 441 patients with cryptogenic stroke and no evidence of AF during 24 h of continuous ECG monitoring were randomly assigned to prolonged monitoring using an implantable loop recorder (monitored group) or a conventionally monitored control group \[[@R12]\]. At 6 months, AF detection was significantly higher in the monitored group (8.9%) and 1.4% in the control group (hazard ratio 6.4, 95% CI: 1.9 - 21.7). Results were similar in the EMBRACE trial \[[@R13]\]. These studies confirm that prolonged cardiac event monitoring can significantly increase the detection of idiopathic AF in patients who experience TIA or acute ischemic stroke.

In hopes of reducing the risk of embolic events and aiding patients with symptom mitigation, we would thus argue that asymptomatic to minimally symptomatic patients be urged to consider intervention despite appearing asymptomatic.

Limitations {#s4a}
-----------

There were several limitations to the study. First, the patients were not randomized or subjected to uniform treatment. Second, a placebo effect must be considered, in AF, patients' anxiety and depression can exacerbate the symptoms and treatment of any sort may lessen the anxiety a patient has in regard to their condition \[[@R14]\]. Lastly, the revised baseline SAF being assessed in retrospect makes it subject to recall bias.

Conclusions {#s4b}
-----------

In the vast majority of our patients with asymptomatic to minimally symptomatic AF, the true extent of symptom compensation was realized following intervention. Appearing asymptomatic should not deter urging the patient to attempt rhythm control or rate control therapy for AF management. Treatment should be considered in all AF patients, including those presenting asymptomatic and minimally symptomatic.
